Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R4


Brief Information

Name:Fibroblast growth factor receptor 4
Target Synonym:EC 2.7.10,EC:,Fibroblast growth factor receptor 4,CD334,FGFR4,TKF,JTK2,Tyrosine Kinase Related To Fibroblast Growth Factor Receptor,Hydroxyaryl-Protein Kinase,Protein-Tyrosine Kinase,Tyrosylprotein Kinase,CD334 Antigen,EC,FGFR-4,Receptor, Fibroblast Growth Factor, Type 4
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FG4-H5253 Human Human FGF R4 / CD334 Protein, Fc Tag
FG4-M52Ha Mouse Mouse FGF R4 / CD334 Protein, His Tag
FG4-H5228 Human Human FGF R4 / CD334 Protein, His Tag

Part of Bioactivity data

Human FGF R4, His TagHuman FGF R4, His Tag (Cat. No. FG4-H5228) ELISA bioactivity

Immobilized Human FGF R4, His Tag (Cat. No. FG4-H5228) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.02-1.25 μg/mL (QC tested).

Mouse FGF R4, His TagMouse FGF R4, His Tag (Cat. No. FG4-M52Ha) ELISA bioactivity

Immobilized Mouse FGF R4, His Tag (Cat. No. FG4-M52Ha) at 2 μg/mL (100 μL/well) can bind Human FGF-9, Fc Tag (Cat. No. FG9-H4267) with a linear range of 0.156-5 μg/mL (QC tested).

Synonym Name



Fibroblast growth factor receptor 4(FGFR4) is also known as CD334, JTK2,  hydroxyaryl-protein kinase, TKF, protein-tyrosine kinase . The FGFR4 gene provides instructions for making a protein called fibroblast growth factor receptor 4. This protein is part of a family of fibroblast growth factor receptors that share similar structures and functions. These receptor proteins play a role in important processes such as cell division, regulating cell growth and maturation, formation of blood vessels, wound healing, and embryo development.The FGFR4 protein interacts with specific growth factors to conduct signals from the environment outside the cell to the nucleus. The nucleus responds to these signals by switching on or off appropriate genes that help the cell adjust to changes in the environment. In response, the cell might divide, move, or mature to take on specialized functions. Although specific functions of FGFR4 remain unclear, studies indicate that the gene is involved in muscle development and the maturation of bone cells in the skull. The FGFR4 gene may also play a role in the development and maintenance of specialized cells (called foveal cones) in the light-sensitive layer (the retina) at the back of the eye.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib G-024; JNJ-493; 890E37NHMV; JNJ-42756493 Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Lymphoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Lenvima, Lenvima/Kisplyx, 乐卫玛, Kisplyx Japan Carcinoma, Renal Cell Merck Sharp & Dohme Corp 2015-02-13 Carcinoma, Adenoid Cystic; Thrombosis; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Lymphoma; Thyroid Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Neuroendocrine Tumors; Solid tumours; Urinary Bladder Neoplasms; Adenocarcinoma, Follicular; Liver Diseases; Small Cell Lung Carcinoma; Neoplasms; Kidney Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SY-4798 Phase 1 Clinical Shouyao Holding (Beijing) Co Ltd Solid tumours Details
BPI-43487 BPI-43487 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular Details
HS-10340 HS-10340 Phase 1 Clinical Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd Solid tumours Details
JAB-6343 Phase 1 Clinical Jacobio Pharmaceuticals Co Ltd Solid tumours Details
SYHX-2005 SYHX-2005; SYHX2005 Phase 1 Clinical Cspc Ouyi Pharmaceutical Co Ltd Solid tumours Details
Roblitinib FGF-401; NVP-FGF401 Phase 2 Clinical Novartis Pharma Ag Neoplasms; Carcinoma, Hepatocellular Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Lung Neoplasms Details
LY-2874455 LY-2874455 Eli Lilly And Company Details
INCB-62079 INCB-62079; INCB-062079 Incyte Corp Details
H3B-6527 H3B-6527 H3 Biomedicine Inc Details
EVER-4010001 EVER-4010001 Phase 2 Clinical EverNov Medicines (Zhuhai Hengqin) Co Ltd Solid tumours Details
ZSP-1241 ZSP-1241 Phase 1 Clinical Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd Biliary Tract Neoplasms; Liver Neoplasms; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Colorectal Neoplasms Details
ASP-5878 ASP-5878 Astellas Pharma Inc Details
U3-1784 U3-1784 U3 Pharma Details
Fisogatinib BLU-554; CS-3008 Phase 2 Clinical Blueprint Medicines Corp Carcinoma, Hepatocellular Details
Rogaratinib BAY-1163877 Phase 2 Clinical Bayer AG Carcinoma, Transitional Cell; Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung Details
ODM-203 ODM-203 Orion Corp Details
ICP-105 ICP-105 Phase 1 Clinical Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd Liver Neoplasms; Solid tumours Details
SC-0011 SC-0011 Phase 1 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours Details
Aldafermin M-70; NGM-282 Phase 2 Clinical Ngm Biopharmaceuticals Liver Cirrhosis, Biliary; Constipation; Non-alcoholic Fatty Liver Disease; Renal Insufficiency; Irritable Bowel Syndrome; Fibrosis; Cholangitis, Sclerosing; Diarrhea; Hepatic Insufficiency; Diabetes Mellitus; Malabsorption Syndromes Details
ABSK-011 ABSK-011 Phase 2 Clinical ABbisko Therapeutics Co Ltd Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular Details
HS-236 HS-236 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message